

Human CD62P ELISA Kit

Instructions for use

Catalogue numbers: 1x48 tests: EA101259

1x96 tests: EA101260 2x96 tests: EA101261

For research use only

Fast Track Your Research.....

Table of Contents

1.	Intended use	2
2.	Summary	
2. 3.	Principle of the method	
4.	Reagents provided and reconstitution	
5.	Materials required but not provided	3
6.	Storage Instructions	3
7.	Specimen collection, processing & storage	4
8.	Safety & precautions for use	5
9.	Assay Preparation	6
9.1.	Assay Design	6
9.2.	Preparation of Wash Buffer	6
9.3.	Preparation of Standard Diluent Buffer	6
9.4.	Preparation of Standard	7
9.5.	Preparation of Samples	7
9.6.	Preparation of Biotinylated anti-CD62P	7
9.7.	Preparation of Streptavidin-HRP	8
10.	Method	9
11.	Data Analysis	10
12.	Assay limitations	10
13.	Performance Characteristics	11
13.1.	Sensitivity	11
13.2.	Precision	11
13.1.	Specificity	11
13.2.	Dilution Parallelism	11
13.3.	Spike Recovery	11
13.4.	Stability	11
13.5.	Normal Serum Values	11
14.	Bibliography	11
15.	References	11
16.	Assay Summary	13

Human CD62P (P-Selectin) ELISA KIT

1. Intended use

The OriGene Human CD62P ELISA is to be used for the in-vitro quantitative determination of CD62P (P-Selectin), in supernatant, buffered solutions or serum and plasma samples. The assay will recognize both natural and recombinant human CD62P.

This kit has been configured for research use only.

2. Summary

P-selectin (CD62P, LECAM-3) was originally purified from platelets and later found to be expressed also in endothelial cells. In both cell types, P-selectin is constitutively expressed and stored in secretory granules – α-granules in platelets and Weibel-Palade bodies in endothelial cells (1)

A soluble form of P-selectin, which might represent a proteolytic fragment or a soluble splice variant lacking the transmembrane domain, is found in serum and plasma (2). High expression of P-selectin or sP-selectin has been implicated in several inflammatory disorders, including adult respiratory distress syndrome, acute lung injury, ischemia-reperfusion injury, Gram-negative septic shock, thrombotic diseases, malaria, systemic sclerosis, connective tissue disease and rheumatoid arthritis. Furthermore, lung injury scores correlate significantly with sP-selectin in plasma of patients with acute lung injury (3) and (4).

3. Principle of the method

The CD62P Kit is a solid phase sandwich <u>Enzyme Linked-Immuno-Sorbent Assay</u> (ELISA). A monoclonal antibody specific for CD62P has been coated onto the wells of the microtiter strips provided. Samples, including standards of knownCD62Pconcentrations and unknowns are pipetted into these wells.

During the first incubation, the CD62P antigen, standards and zeros are bound this is followed by a separate incubation where the biotinylated monoclonal antibody specific for CD62P is added.

After washing, the enzyme (streptavidin-peroxydase) is added. After incubation and washing to remove all the unbound enzyme, a substrate solution is added to induce a coloured reaction product. The intensity of this coloured product is directly proportional to the concentration of CD62P present in the samples.

4. Reagents provided and reconstitution

Reagents (Store@2-8°C)	Quantity 1x48 well kit Cat no. EA101259	Quantity 1x96 well kit Cat no. EA101260	Quantity 2x96 well kit Cat no. EA101261	Reconstitution		
96 well microtiter strip plate	1/2	1	2	Ready to use (Pre-coated)		
Plastic plate covers	2	2	4	n/a		
Standard: 140 ng/ml	1 vial	2 vials	4	Reconstitute as directed on the vial (see Assay preparation, section 8)		
Standard Diluent (Buffer)	d Diluent (Buffer) 1 vial (25ml) 1 vial (25ml) 1 vial (25ml)		1 vial (25ml)	10x Concentrate, dilute in distilled water (see reagent preparation, section 8)		
Biotinylated anti-CD62P	inylated anti-CD62P 1 vial (0.3ml) 1 vial (0.3ml) 2 vials (0.3ml)		2 vials (0.3ml)	Dilute in Biotinylated Antibody Diluent (see Assay preparation, section 8)		
Biotinylated Antibody Diluent	1 vial (7ml)	1 vial (7ml)	1 vial (13ml)	Ready to use		
Streptavidin-HRP	1 vial (5μl)	2 vials (5μl)	4 vials (5μl)	Add 0.5ml of HRP diluent prior to use (see Assay preparation, section 8)		
HRP Diluent	1 vial (23ml)	1 vial (23ml)	1 vial (23ml)	Ready to use		
Wash Buffer	Wash Buffer 1 vial (10ml) 1 vial (10ml) 2 v		2 vials (10ml)	200x Concentrate dilute in distilled water (see Assay preparation, section 8)		
TMB Substrate	1 vial (11ml)	1 vial (11ml)	1 vial (24ml)	Ready to use		
H ₂ SO ₄ stop reagent	1 vial (11ml)	1 vial (11ml)	2 vials (11ml)	Ready to use		

5. Materials required but not provided

- Microtiter plate reader fitted with appropriate filters (450nm required with optional 630nm reference filter)
- Microplate washer or wash bottle
- 10, 50, 100, 200 and 1,000µl adjustable single channel micropipettes with disposable tips
- 50-300µl multi-channel micropipette with disposable tips
- Multichannel micropipette reagent reservoirs
- Distilled water
- Vortex mixer
- Miscellaneous laboratory plastic and/or glass, if possible sterile

6. Storage Instructions

Store kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the kit and reagents is stated on box front labels. The expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, the reagent is not contaminated by the first handling.

Wash Buffer: Once prepared store at 2-8° C for up to 1 week

Standard Diluent Buffer: Once prepared store at 2-8° C for up to 1 week

Standards: Once prepared use immediately and do not store

Biotinylated Secondary Antibody: Once prepared use immediately and do not store

Streptavidin-HRP: Once prepared use immediately and do not store

7. Specimen collection, processing & storage

Cell culture supernatants, serum, plasma or other biological samples will be suitable for use in the assay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting and separation.

Cell culture supernatants: Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

Serum: Avoid any unintentional stimulation of the cells by the procedure. Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clothing. For that, after clothing, centrifuge at approximately 1000 x g for 10 min and remove serum.

Plasma: EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

Storage: If not analyzed shortly after collection, samples should be aliquoted (250-500µI) to avoid repeated freeze-thaw cycles and stored frozen at -70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

Recommendation: Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use. When possible avoid use of badly haemolysed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

8. Safety & precautions for use

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures , e.g.CDC/NIH Health manual : " Biosafety in Microbiological and Biomedical Laboratories" 1984
- The human serum included in this kit have been tested and found non reactive for HbsAg, anti HIV1 & 2
 and anti VHC. Nevertheless, no known method can offer complete assurance that human blood
 derivatives will not transmit hepatitis, AIDS or other infections. Therefore handling of reagents, serum or
 plasma specimens should be in accordance with local safety procedures
- Laboratory gloves should be worn at all times
- Avoid any skin contact with H₂SO₄ and TMB. In case of contact, wash thoroughly with water
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used
- Do not pipette by mouth
- When not in use, kit components should be stored refrigerated or frozen as indicated on vials or bottles labels
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration
- · Cover or cap all reagents when not in use
- Do not mix or interchange reagents between different lots
- Do not use reagents beyond the expiration date of the kit
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of H₂SO₄ and substrate solution, avoid pipettes with metal parts
- Use a clean plastic container to prepare the washing solution
- Thoroughly mix the reagents and samples before use by agitation or swirling
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells
- The TMB solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB solution with metal to prevent colour development. Warning TMB is toxic avoid direct contact with hands. Dispose off properly
- If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbance's within 1 hour after completion of the assay
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells
- Follow incubation times described in the assay procedure
- Dispense the TMB solution within 15 min of the washing of the microtitre plate

9. Assay Preparation

Bring all reagents to room temperature before use

9.1. Assay Design

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard and zero should be tested **in duplicate**. Remove sufficient microwell strips for testing from the pouch immediately prior to use. Return any wells not required for this assay with desiccant to the pouch. Seal tightly and return to 2-8°C storage.

Example plate layout(example shown for a 6 point standard curve)

	Standards		Sample Wells									
	1	2	3	4	5	6	7	8	9	10	11	12
Α	140	140										
В	70	70										
С	35	35										
D	17.5	17.5										
E	8.8	8.8										
F	4.4	4.4										
G	zero	zero										
Н												

All remaining empty wells can be used to test samples in duplicate

9.2. Preparation of Wash Buffer

Dilute the (200x) wash buffer concentrate 200 fold with distilled water to give a 1x working solution. Pour entire contents (10 ml) of the Washing Buffer Concentrate into a clean 2,000 ml graduated cylinder.Bring final volume to 2,000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. Transfer to a clean wash bottle and store at 2°-8°C for up to 1 week.

9.3. Preparation of Standard Diluent Buffer

Add the contents of the vial (10x concentrate) to 225ml of distilled water before use.

This solution can be stored at 2-8°C for up to 1 week.

9.4. Preparation of Standard

Standard vials must be reconstituted with the volume of standard diluent shown on the vial immediately prior to use. This reconstitution gives a stock solution of 140ng/ml of CD62P. **Mix the reconstituted standard gently by inversion only**. Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 140 to 4.4ng/ml. A fresh standard curve should be produced for each new assay.

- Immediately after reconstitution add 200µl of the reconstituted standard to wells A1 and A2, which provides the highest concentration standard at 140ng/ml
- Add 100μl of Standard Diluent to the remaining standard wells B1 and B2 to F1 and F2
- Transfer 100µl from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells
- Continue this 1:1 dilution using 100μl from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 140 to 4.4ng/ml
- Discard 100μl from the final wells of the standard curve (F1 and F2)

Alternatively these dilutions can be performed in separate clean tubes and immediately transferred directly into the relevant wells.

9.5. Preparation of Samples

Before testing, serum or plasmas samples have to be diluted 1:5 in standard buffer diluent.

9.6. Preparation of Biotinylated anti-CD62P

It is recommended this reagent is prepared immediately before use. Dilute the biotinylated anti-CD62P with the biotinylated antibody diluent in an appropriate clean glass vial using volumes appropriate to the number of required wells. Please see example volumes below:

Number of wells	Biotinylated	Biotinylated		
required	Antibody (μl)	Antibody Diluent (μl)		
16	40	1060		
24	60	1590		
32	80	2120		
48	120	3180		
96	240	6360		

9.7. Preparation of Streptavidin-HRP

It is recommended to centrifuge vial for a few seconds in a microcentrifuge to collect all the volume at the bottom.

Dilute the 5μ l vial with 0.5ml of HRP diluent **immediately before use.** Do-not keep this diluted vial for future experiments. Further dilute the HRP solution to volumes appropriate for the number of required wells in a clean glass vial. Please see example volumes below:

Number of wells	Streptavidin-HRP	Streptavidin-HRP
required	(µl)	Diluent (ml)
16	30	2
24	45	3
32	60	4
48	75	5
96	150	10

10. Method

We strongly recommend that every vial is mixed thoroughly without foaming prior to use except the standard vial which must be mixed gently by inversion only.

Prepare all reagents as shown in section 9.

Note: Final preparation of Biotinylated anti-CD62P (section 9.6) and Streptavidin-HRP (section 9.7) should occur immediately before use.

As	ssay Step	Details
1.	Addition	Prepare Standard curve as shown in section 9.4
2.	Addition	Add 100 µl of each standard, sampleand zero (Standard Diluent) in duplicate to appropriate number of wells
3.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 1 hour
4.	Wash	Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.3 ml of 1x washing solution into each well c) Aspirate the contents of each well d) Repeat step b and c another two times
5.	Addition	Add 50μl of diluted biotinylated anti-CD62P to all wells
6.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 1 hour
7.	Wash	Repeat wash step 4.
8.	Addition	Add 100µl of Streptavidin-HRP solution into all wells
9.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 30 min
10.	Wash	Repeat wash step 4.
11.	Addition	Add 100µl of ready-to-use TMB Substrate Solution into all wells
12.	Incubation	Incubate in the dark for 10-20 minutes * at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil
13.	Addition	Add 100µl of H ₂ SO ₄ :Stop Reagent into all wells

Read the absorbance value of each well (immediately after step 13.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 630 nm as the reference wave length (610 nm to 650 nm is acceptable).

^{*}Incubation time of the substrate solution is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range

11. Data Analysis


Calculate the average absorbance values for each set of duplicate standards and samples. Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding murine CD62P standard concentration on the horizontal axis.

The amount of CD62P in each sample is determined by extrapolating OD values against CD62P standard concentrations using the standard curve.

Example CD62P Standard curve

Standard	CD62P Conc (ng/ml)	OD (450nm) Mean	CV (%)
1	140	1.992	2.0
2	70	1.050	0.7
3	35	0.429	0.0
4	17.5	0.172	2.9
5	8.75	0.079	2.1
6	4.37	0.046	7.8
Zero	0	0.020	-



Note; curve shown above should not be used to determine results. Every laboratory must produce a standard curve for each set of microwell strips assayed.

For sample serum or plasmas which have been diluted 1:5 according to the protocol, the calculated concentration should be multiplied by the dilution factor (x5)

12. Assay limitations

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Standard diluent or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results.

Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Washing Buffer, fill with Washing Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore **afresh standard curve must be prepared and run for every assay.**

13. Performance Characteristics

Intra-Assav

13.1. Sensitivity

The sensitivity, minimum detectable dose of HumanCD62P using this OriGeneCD62P ELISA kit was found to be **<3.6ng/ml**. This was determined by adding 3 standard deviations to the mean OD obtained when the zero standard was assayed 32times.

13.2. Precision

		•					•		
Sample	n	Mean (ng/mL)	SD	CV%	Sample	n	Mean (ng/mL)	SD	CV%

Sample	n	Mean (ng/mL)	SD	CV%	Sample	n	Mean (ng/mL)	SD	CV%
A	6	90.4	5	5.6	A	18	92	6.9	7.5
В	6	39.6	3.1	7.8	В	18	42.3	1.8	4.4

Inter-Assav

13.1. Specificity

Ten specificities were tested. No cross reaction was observed for MICA, gp130, GM-CSF, IL-2, IL-6, TRAIL, IL-13, IL-8, Perforin and CD31

13.2. Dilution Parallelism

One pooled human serum sample was serially diluted in standard diluent buffer. Linearity was evaluated on 4 dilutions. The recovery ranged between 95.1% and 112.6% with an **overall mean recovery of 101.3%**

13.3. Spike Recovery

The spike recovery was evaluated by spiking recombinant CD62P into human serum. The calculated **mean recovery is 97.3%.**

13.4. Stability

Storage Stability

Aliquots of a serum sample (unspiked with CD62P) were stored at –20°C, 2-8°C, room temperature and at 37°C, and the CD62P levels determined after 24 hours. There was no significant loss of CD62P immunoreactivity during storage under above conditions.

Freeze-thaw Stability

Aliquots of serum samples (unspiked with CD62P) were stored at –20°C and thawed and frozen several times, and the CD62P levels determined. There was no significant loss of CD62P concentrations between 0 and 5 freeze-thaw cycles.

13.5. Normal Serum Values

A panel of 22 sera from apparently healthy blood donors (male and female) was tested for CD62P. The detected CD62P levels ranged between 124 and 539.8 ng/ml with a mean level of 348.5 ng/ml and a standard deviation of \pm 116.6 ng/ml.

14. Bibliography

- **1.** R.P. McEver *et al.*, GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies, *J. Clin. Invest.***84** (1989), pp. 92–99.
- **2.** S. Ushiyama *et al.*, Structural and functional characterization of monomeric soluble P-selectin and comparison with membrane P-selectin, *J. Biol. Chem.***268** (1993), pp. 15229–15237.
- **3.** D. Marshall and D.O. Haskard, Clinical overview of leukocyte adhesion and migration: where are we now?, *Semin. Immunol.***14** (2002), pp. 133–140.
- **4.** C. Ehrhardt *et al.*, Selectins an emerging target for drug delivery, *Adv. Drug Deliv. Rev.***56** (2004), pp. 527–549.

15. References

Chirico, E.N. et al. Exercise training blunts oxidative stress in sickle cell trait carriers. J Appl Physiol, 2012; 112: 1445 – 1453

Cosentino, F. et al. Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects: A Study WithTechnetium-99m-Ethyl Cysteinate Dimer Single Photon Emission Computed Tomography. Stroke,2009; 40(1): 306-308

Tripette, J. et al. Patterns of exercise-related inflammatory response in sickle cell trait carriers. Br. J. Sports Med.,2010;44(4): 232-237

Vincent, L. et al. Remodeling of skeletal muscle microvasculature in sickle cell trait and {alpha}-thalassemia.., Am J Physiol Heart Circ Physiol.,2009:00812.2009

16. Assay Summary

Total procedure length: 2h45mn

Add 100µl sample, diluted standard and control

1

Incubate 1 hour at room temperature

 \downarrow

Wash three times

 \downarrow

Add 50µl of Biotinylated anti-CD62P

 \downarrow

Incubate 1 hourat room temperature

 \downarrow

Wash three times

 \downarrow

Add 100µl of Streptavidin-HRP

 \downarrow

Incubate 30min at room temperature

↓

Wash three times

1

 $\label{eq:Add 100 multiple} Add 100 \; \mu l \; \; of \; ready-to-use \; TMB \\ Protect from light. \; Let the color develop for \; 10-20 \; min. \\$

ļ

Add 100 H₂SO₄

 \downarrow

Read Absorbance at 450 nm

TECHNICAL CONSULTATION

OriGene Technologies, Inc. 9620 Medical Center Dr., Suite 200 Rockville, MD 20850

Phone: 1.888.267.4436 Fax: 301-340-9254 Email: techsupport@origene.com Web: www.origene.com

For Research Use Only Not for use in diagnostic procedures